Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Los Angeles, CA
NPI: 1366737231Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get M.D. Caspian's Phone Numberphone_androidMobile
Get M.D. Caspian's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2012 - 2026
PA State Medical License
2011 - 2012
CA State Medical License
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
Drexel University College Of Medicine
drexel.edu
Medical School
Until 2011
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
2016 - 2019
Residency • Internal Medicine
2014 - 2016
California Pacific Medical Center
Residency • Radiation Oncology
2012 - 2016
Drexel University College of Medicine/Hahnemann University Hospital
Internship • Internal Medicine
2011 - 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 214 | 378 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 186 | 404 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 123 | 288 |
| 4 | J7050Infusion, normal saline solution , 250 cc | 95 | 250 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 57 | 57 |
Authors: Jeffrey Veale, Neil Kogut, Nima Nassiri, Erik Lum
Journal: Lancet
SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.
Authors: Jun Yang, Stephen Arrigo, Bruce Garber
Publication Date: 2014-09-01
How to address second and therapy-related acute myelogenous leukaemia.
Authors: Gary Schiller
Publication Date: 2019-12-22
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Azacitidine, DRUG: Sabatolimab
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Stemline Therapeutics, Inc.
Intervention / Treatment: DRUG: Azacitidine, BIOLOGICAL: Tagraxofusp-erzs
Lead Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: AstraZeneca
Intervention / Treatment: DRUG: Acalabrutinib